alpha glucosidase
/ Pharming Group
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 01, 2020
Pharming N : Group reports financial results for the first half of 2020
(Market Screener)
- "For the remainder of 2020, the Company expects:...Investment in an Investigational New Drug Application to the FDA enabling studies for α- glucosidase in Pompe disease and preclinical development of the new recombinant α- galactosidase candidate for Fabry's disease."
New trial • Preclinical • Fabry Disease • Genetic Disorders • Pompe Disease
1 to 1
Of
1
Go to page
1